This study provides fundamental information on how Arg-II participates in cardiac aging. The phenotypic data provide convincing evidence of non-cell-autonomous contributions to aging-related ...
Over the course of evolution, the human heart has largely lost its ability to regenerate. Our distant ancestors were not ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Dyne Therapeutics leverages its differentiated FORCE platform for targeted delivery in rare neuromuscular diseases, supporting a premium valuation. DYN-101 and DYNE-251 show early promise in DM1 and ...
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trial HOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmission Company preparing to resubmit CRL response ...
Danielle “Nellie” Bruns, an associate professor in the University of Wyoming’s Department of Zoology and Physiology, has received a five-year, $1.78 million research grant from the National Institutes ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Fibrosis, marked by excessive extracellular ...
Titin, the largest known protein in the human body, spans half of the sarcomere and plays essential roles in muscle elasticity, active and passive force regulation, and mechanosensing, thereby ...
1 Department of Kinesiology, University of Maryland School of Public Health, College Park, Maryland, MD, United States 2 Baltimore Veterans Affairs Geriatric Research, Education and Clinical Center, ...
Advice to improve your movement, fitness, and overall health from the #1 in orthopedics in the U.S. Maintaining your arm muscles is about more than flexing impressive biceps. While the arm muscles, ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 – Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 – Data expected for SRP-9003 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback